Appendix 4C Quarterly Activity Report
January 31, 2023 04:40 ET
|
Mesoblast Limited
NEW YORK, Jan. 31, 2023 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today provided an activity report for...
Mesoblast and Oaktree Extend Availability Period of Undrawn Tranches of Financing Facility
December 22, 2022 19:18 ET
|
Mesoblast Limited
NEW YORK, Dec. 22, 2022 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today announced that funds managed by...
Children Treated With Remestemcel-L Show Long-Term Survival Through Four Years in Steroid-Refractory Acute Graft Versus Host Disease (SR-aGVHD)
November 22, 2022 18:32 ET
|
Mesoblast Limited
Key Points: Long-term survival evident through 4 years in children treated with remestemcel-L in Phase 3 trial MSB-GVHD001Overall survival at 2 years was 51% in remestemcel-L treated children and...
Mesoblast Reports Financial Results and Operational Highlights for the Period Ended September 30, 2022
November 22, 2022 18:01 ET
|
Mesoblast Limited
Durable long-term survival outcomes through 4 years for children with steroid-refractory graft versus host disease (SR-aGVHD) treated with remestemcel-L These long-term survival outcomes are a...
Mesoblast Financial Results and Corporate Update Webcast
November 21, 2022 06:00 ET
|
Mesoblast Limited
NEW YORK, Nov. 21, 2022 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, will host a webcast to discuss...
Mesoblast Operational and Financial Highlights for Quarter Ended September 30, 2022
October 30, 2022 19:50 ET
|
Mesoblast Limited
NEW YORK, Oct. 30, 2022 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today provided an activity report for...
Mesoblast Submits New Information to FDA IND File in Response to Items in the CRL to the Remestemcel-L BLA for SR-aGVHD
October 02, 2022 19:52 ET
|
Mesoblast Limited
NEW YORK, Oct. 02, 2022 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, announced today that it has submitted...
Mesoblast Reports Financial Results and Operational Highlights for Fiscal Year Ended June 30, 2022
August 30, 2022 19:05 ET
|
Mesoblast Limited
At June 30, 2022, cash-on-hand was US$60.4 million with pro-forma US$105.5 million after raising gross proceeds of US$45 million via a private placement in August, 2022 Up to an additional US$40...
Mesoblast Corporate Update and Financial Results Webcast
August 29, 2022 20:14 ET
|
Mesoblast Limited
NEW YORK, Aug. 29, 2022 (GLOBE NEWSWIRE) -- Mesoblast Limited (ASX:MSB; Nasdaq:MESO), global leader in allogeneic cellular medicines for inflammatory diseases, will host a webcast to discuss...
Jane Bell Joins Mesoblast Board
August 18, 2022 07:00 ET
|
Mesoblast Limited
NEW YORK, Aug. 18, 2022 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today announced that it has appointed...